TCRX
Tscan Therapeutics Inc
NASDAQ: TCRX · HEALTHCARE · BIOTECHNOLOGY
$1.15
-8.73% today
Updated 2026-04-29
Market cap
$75.73M
P/E ratio
—
P/S ratio
7.33x
EPS (TTM)
$-1.00
Dividend yield
—
52W range
$1 – $3
Volume
0.9M
Tscan Therapeutics Inc (TCRX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-12.52M | $-3.02M | $-48.68M | $-66.50M | $-61.36M | $-110.82M | $-135.32M |
| Capital expenditures | $1.25M | $4.24M | $9.94M | $4.22M | $3.15M | $3.83M | $4.41M |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $240000.00 | $515000.00 | $2.52M | $4.55M | $5.21M | $9.55M | $11.71M |
| Free cash flow | $-13.77M | $-7.26M | $-58.62M | $-70.73M | $-64.50M | $-114.65M | $-139.73M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | $0.00 | $0.00 |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $131.05M | $-41.37M | — | — | — |